Collecting blood and clot samples from people with a large-vessel stroke
Collects samples and health records from people with a blocked large brain artery stroke.
Plain-language title generated from the registry record
Registry title: Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort
Key facts
- Where
- Baotou, Beijing, Henan, Jinan, and Wuhu, ChinaSee the 5 sites
Where in China
- Baotou Central HospitalBaotou, ChinaTaking people
- Capital medical university of Beijing Tiantan HospitalBeijing, ChinaTaking people
- The First Affiliated Hospital of Zhengzhou UniversityHenan, ChinaTaking people
- Affiliated Hospital of Shandong University of Traditional Chinese Medicine HospitalJinan, ChinaTaking people
- The First Affiliated Hospital of Shihezi UniversityWuhu, ChinaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Wannan Medical College
- Trial code
- NCT06963489
- Record updated
- 11 May 2025
- Original description
This multicenter, ambispective cohort study establishes a comprehensive multiomics biobank from five stroke centers, encompassing thrombi, intracranial blood, peripheral arterial/venous blood, and clinical-laboratory-imaging-follow-up data from patients with acute ischemic stroke with large vessel occlusion (AIS-LVO).Read full original descriptionShow less
Cerebral Large Vessel Occlusion Stroke Multiomics Biosample Cohort
This multicenter, ambispective cohort study establishes a comprehensive multiomics biobank from five stroke centers, encompassing thrombi, intracranial blood, peripheral arterial/venous blood, and clinical-laboratory-imaging-follow-up data from patients with acute ischemic stroke with large vessel occlusion (AIS-LVO).
Inclusion: Age over 18 years; Patients with intracranial and extracranial large vessel occlusion ischemic stroke confirmed by cerebrovascular angiography; Availability of complete clinical and follow-up information required for the study; Availability of blood and/or thrombus biological samples; Voluntary written informed consent signed by the patient or their family (1) For retrospectively enrolled patients, a "broad informed consent" was signed at the time of sample collection. Upon enrollment into the cohort, a follow-up phone call was made to confirm the informed consent; (2) For prospectively enrolled patients, informed consent for this study was signed at the time of enrollment by the patient or their family.
Exclusion: Patients for whom biological samples cannot be obtained; Patients or their family members who refuse to sign the informed consent form.